Biocompatibility evaluation of various blood purification therapies

Biocompatibility evaluation of various blood purification therapies - Biocompatibility evaluation of various blood purification therapies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040267

Enrollment

Registered

2020-05-01

Start date

2016-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with end-stage renal failure undergoing hemodialysis

Interventions

Perform pre-dilution online HDF and post-dilution online HDF using MFX-25Ueco (Nipro Corporation) for 2 weeks. HD with PES-25Da eco (Nipro Corporation) is performed for 2 weeks before and after each t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Regardless of gender, hospitalization / outpatient status, medical history, or presence of complications

Exclusion criteria

Exclusion criteria: Patients with C-reactive protein (CRP); 0.3 mg / dL or more by prior blood test

Design outcomes

Primary

Measure	Time frame
White blood cell count, platelet count, high-sensitivity CRP, plateletderived micro particles change rate and PTX3, IL-6 production rate before and after treatment	—

Secondary

Measure	Time frame
Albumin leakage, transmembrane pressure difference	—

Countries

Japan

Contacts

Public ContactHiroyuki Michiwaki

Kawashima hospital Department of Clinical Engineering

michiwaki@khg.or.jp088-631-0110

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026